At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 81 enrolled
Drug / intervention
KQ-791 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of KQ-791 in Subjects With Type 2 Diabetes
In Brief
A Phase 1 clinical trial evaluating KQ-791 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 81 participants across 4 sites.
Detailed Summary
This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJun 2015
Primary CompletionFeb 2016
TodayJul 2026
First PostedMay 15, 2015
Enrollment StartJun 1, 2015
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.1 years ago
Interventions
KQ-791drug
Capsules administered orally
Placebodrug
Capsules administered orally